Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to investigate the effect of subcutaneous administration of Botulinum toxin A on wound pain, wound healing and safety of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Botulinum Toxin A | Experimental | Open-label study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Botulinum Toxin A | Drug | Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients reaching a reduction in mean visual analog scale (VAS) > 20 mm (at rest) in dynamic pain scores at study day 21 or 41 | At study day 0 the mean VAS will be calculated at rest for D-2-0 and at D21 or D41 mean VAS will be calculated for D19-21 or D39-41 | 3 to 6 weeks after first injection of Botulinum toxin a |
| Measure | Description | Time Frame |
|---|---|---|
| Absolute and percentage change in the area of hyperalgesia and allodynia | Area of hyperalgesia and allodynia will be assessed at D0, D21/41 and D90/110 | 3 to15 weeks after first injection of Botulinum toxin a. |
| Absolute and percentage change of the ulcer area. |
| Measure | Description | Time Frame |
|---|---|---|
| Wound status- Degree of inflammation, granulation tissue, necrosis/slough, exudation and infection. | Semi-quantitatively measured (Absent/Low < 25 %, Mild 25-50 %, Moderate 51-75 %, High > 75%) | Throughout the trial (12-15 weeks) |
Inclusion Criteria:
Exclusion Criteria:
1. Infection at injection site. 2. Hypersensitivity to botulinum toxin A. 3. Peripheral neuropathy. 3. Diabetic foot ulcer. 4. Unstable critic peripheral ischemia judged by investigator 5. Exposed capsule, tendon, muscle or bone in the ulcers. 6. Tunnelling, undermining or sinus tracts. 7. Disorders of the neuromuscular junction (e.g. Myasthenia). 8. Topical analgesic (e.g Biatain ibu or Lidocain) within 7 days before inclusion.
9. Pregnant or lactating woman and woman with childbearing potential but does not use contraception.
10. Judgment by the investigator that the patient is not suited for study participation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Simon Francis Thomsen, Professor | Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital | Copenhagen | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D019274 | Botulinum Toxins, Type A |
| ID | Term |
|---|---|
| D001905 | Botulinum Toxins |
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
Not provided
Not provided
A single-center, prospective, exploratory study
Not provided
Not provided
Not provided
Not provided
|
The ulcer size will be measured at every visit with study day 0 as baseline. |
| Throughout the trial (12-15 weeks) |
| Clinical improvement of the wound healing process | Semi-quantitatively measured (major improvement, minor improvement, status quo or worsening) | Throughout the trial (12-15 weeks) |
| Therapeutic doses of Botulinum toxin a to treat wound pain | Number of patients who need a second injection of Botulinum toxin a on study D21 if mean VAS (D19-21) are similar (± 10 %) to the pre-injection mean VAS at D0 | 3 and 6 weeks after first injection |
| Incidence of Treatment-Emergent Adverse Events | All clinical adverse events will be assessed and recorded. | Throughout the trial (12-15 weeks) |
| Exploratory measurement: Changes in the levels of cytokines and pain related substances in the wound fluid before and after injection with Botulinum toxin a | Changes in the levels of cytokine and pain related substances will be quantified over time (throughout the trial). Prospects to analyse i.g ( IL-6, NGF, IL-1β) with either MSD,Luminex or ELISA. The results will be expressed as pg/ mg. | Analysis within 1 year after study completion |
| D006867 |
| Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
| D001426 | Bacterial Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001427 | Bacterial Toxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |